Gabrielle Wanneh

Maryland

Drug Pricing Reporter at Inside Health Policy

Mark 5:34 || Earthbender 🌿 || Drug pricing reporter @InHealthPolicy by day, vigorously watching cartoons and working on my wildest dreams by night.. 🪴🌻✨

Featured in: Favicon

insidehealthpolicy.com Favicon

msn.com

usnews.com Favicon

yahoo.com

politico.com Favicon

edweek.org Favicon

aarp.org

dcist.com

whsv.com

afro.com + 6 more

Articles

July DOJ Listening Session Could Coincide With FTC Jump-Starting Case Against PBMs

2 weeks ago | insidehealthpolicy.com | Gabrielle Wanneh |Donna Haseley

The Justice Department and Federal Trade Commission’s plan to hold a July 24 listening session on formulary and benefit barriers that keep drug prices high could coincide with a potential move by FTC to jump-start its stalled case against top pharmacy benefit managers.
Florida Receives Second Extension By FDA To Import Rx Drugs

3 weeks ago | insidehealthpolicy.com | Gabrielle Wanneh

FDA on Monday (June 2) granted Florida a four-month extension until November of its existing Section 804 Importation Program (SIP) authorization to import affordable prescription drugs from Canada to lessen costs for state residents so long as public health and safety isn’t compromised.
CMS Would Assume Responsibility For 340B Under WH Budget Request

4 weeks ago | insidehealthpolicy.com | Gabrielle Wanneh

The fiscal 2026 budget for HHS, released Friday (May 30), suggests shifting the 340B program to operate under CMS after more than 30 years of operation under the Health Resources and Services Administration (HRSA), implementing a proposal leaked earlier this spring to reorganize HHS and create a new division.
Advocates Press OMB To Eliminate Biosimilar PK Study Requirements

1 month ago | insidehealthpolicy.com | Gabrielle Wanneh

As the Trump Administration seeks to accelerate approval for biosimilars, generics and other alternatives to high-cost prescription drugs, the Biosimilars Forum is urging the administration to weed out unnecessary regulatory processes that delay the determination of biosimilar efficacy and safety and give FDA more flexibility to speed new biosimilars to the market.
CBP Warns Drug Makers To Ensure Compliance With MFN EO In Trade Situations

1 month ago | insidehealthpolicy.com | Gabrielle Wanneh

Drug companies must declare prescription drug values matching President Donald Trump’s recent “most favored nation” executive order when submitting import or export documentation to the United States Customs and Border Protection (CBP) or face the fullest extent of violation enforcement measures possible, the agency warned this month.
Trump’s 340B Request Could Further Convolute Existing Program Issues

1 month ago | insidehealthpolicy.com | Gabrielle Wanneh

President Donald Trump’s demand for health centers to make insulin and injectable epinephrine available at low prices offered under the 340B drug discount program is unlikely to solve any of the existing operational issues within the program that stakeholders want resolved, health policy experts tell Inside Health Policy.
Alzheimer’s Advocates Wary Of RFK Jr.’s Rhetoric On Amyloid Drugs

1 month ago | insidehealthpolicy.com | Jessica Karins |Gabrielle Wanneh

HHS Secretary Robert F. Kennedy Jr.’s comments about fraudulent research in treating Alzheimer’s and alleged corruption at the National Institutes of Health (NIH) are raising the specter among advocates that there will be new restrictions on the controversial class of drugs that combat amyloid beta plague in the brain.
ICER Preps For Inaugural Annual Report On Drug List Prices & Access

1 month ago | insidehealthpolicy.com | Gabrielle Wanneh

The Institute for Clinical and Economic Review on Friday (May 23) released a protocol detailing how it plans to gather information for a new report on prescription drug list prices and the barriers patients face when trying to access their medications.
Pharma 340B Rebate Model Stopped For Now As Court Defers To HRSA

1 month ago | insidehealthpolicy.com | Gabrielle Wanneh

Hospitals chalked up an initial win in their bid to stop drug makers from replacing upfront 340B drug discounts with back-end rebates when a federal DC district judge ruled last week the ultimate decision on the policy rests with the Health Resources and Services Administration -- but the win could be short-lived as HRSA has sent warning letters against four drug makers asking them to stop their rebate policies although the Trump administration has yet to issue a broad policy decision.
Draft Guidance For Third Negotiation Cycle Ushers In Part B Drugs & Renegotiation

1 month ago | insidehealthpolicy.com | Gabrielle Wanneh

The latest draft guidance for Medicare drug price negotiations clarifies that a drug company's introduction of a fixed combination drug with an altered formulation and delivery method can no longer reset the timeline for when the original drug is eligible for negotiation, closing a loophole in previous guidance that sources say could have allowed Merck and Bristol Myers Squibb to seek protections for their subcutaneous versions of Part B cancer treatments Keytruda and Opdivo.